

Lamoxsan 150 mg/ml suspension for injection for cattle and pigs

Authorised

- Amoxicillin

Product identification

Medicine name:

Lamoxsan 150 mg/ml suspension for injection for cattle and pigs

Lamoxsan 150 mg/ml szuszpenziós injekció szarvarmarhák és sertések részére

Active substance:

Amoxicillin

Target species:

Cattle

Pig

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Amoxicillin

150.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Cattle

- Meat and offal. 18 day
- Milk. 72 hour

-

Pig

- Meat and offal. 20 day
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CA04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Package description:

Clear PET vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear PET vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear type II glass vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear type II glass vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Alfasan Nederland B.V.

Marketing authorisation date:

9/10/2023

Manufacturing sites for batch release:

Alfasan Nederland B.V.

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

9/10/2023

Reference member state:

Netherlands

Procedure number:

NL/V/0391/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

Generic of:

600000004401

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Package Leaflet and Labelling

Combined File of all Documents

NLV0391001DC_DCP_Lamoxsan final PuAR.pdf